Jfl Life Sciences logo

Jfl Life Sciences financials and balance sheet

NSE: JFLLIFEPharmaceuticals & Biotechnology

Last close ₹10.30down ₹0.50 (4.63%)

Share price at the NSE close on 22 Oct 2026. Previous close ₹10.80.

52-week range of traded prices to 22 Oct 2026
₹8.55Low, 30 Mar 2026₹15.40High, 24 Dec 2025
Market cap
₹34 Cr
P/E
5.0
P/B
0.7
Dividend yield
Nonein the last 12 months
ROE
15.9%
ROCE
15.9%
Debt to equity
0.47
Volume, NSE
6,000100.0% delivered

4 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Jfl Life Sciences annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings

Operating and net margin, per cent

  • Operating margin
  • Net margin

The years either side of a change of basis do not compare. From the year to Mar 2024, the company's revenue for that year, ₹47 Cr, differs from its quarters added, ₹48 Cr.

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue131
  2. Materials and goods−115
  3. Employee costs−1.1
  4. Other expenses−3.6
  5. Operating profit12
  6. Depreciation−1.1
  7. Other income+0.1
  8. One-off items0.0
  9. Finance costs−2.1
  10. Profit before tax8.6
  11. Tax−2.2
  12. Net profit6.4

What the company owns

  • Receivables₹53 Cr
  • Inventory₹35 Cr
  • Plant, investments and other assets₹17 Cr
  • Cash and bank₹1 Cr

What pays for it: net worth and liabilities

  • Net worth₹46 Cr
  • Owed to suppliers₹29 Cr
  • Borrowings₹22 Cr
  • Other liabilities₹9 Cr

Profit and loss

Standalone, ₹ crore, years to March.Jfl Life Sciences quarterly results

₹ croreMar 2023Mar 2024Mar 2025Filed 28 JunMar 2026Filed 29 May
Revenue from operations434782131
394274120
Materials and goods bought353966115
Employee costs2211
Other expenses2174
Operating profit before depreciation45812
Operating margin9.2%9.8%10.0%8.9%
Materials, % of revenue80.9%83.5%80.6%87.5%
Employee costs, % of revenue4.3%4.3%1.2%0.8%
Other expenses, % of revenue5.7%2.4%8.2%2.7%
Depreciation and amortisation0011
Operating profit after depreciation44711
Other income2100
Finance costs1112
One-off items0000
Profit before tax4469
1022
Net profit3446
Other comprehensive income––00
Total comprehensive income––46
Net margin6.6%7.5%5.1%4.9%

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2025Filed 28 JunMar 2026Filed 29 May
3946
Share capital3333
Reserves613
1122
3253
17
Total assets72106
1215
6092
Net debt1120
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2023 and Mar 2024, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2025Filed 28 JunMar 2026Filed 29 May
−3.5−4.3
−2.5−4.2
−10.7−16.0
Receivables−9.1−18.3
Inventories−7.4−11.3
Payables5.211.5
Other working capital0.62.1
Tax paid−1.00.0
Interest paid0.00.0
Capital spending0.43.4
Free cash flow−3.9−7.7
0.0−3.9
3.59.1
Dividends paid0.30.0
Shares bought back0.00.0
Shares issued0.00.0
Net change in cash0.00.8
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2023 and Mar 2024.

Per share

Standalone, ₹ per share, years to March.Jfl Life Sciences dividend history

₹ per shareMar 2023Mar 2024Mar 2025Filed 28 JunMar 2026Filed 29 May
Earnings per share––₹1.26₹1.94
Diluted earnings per share––₹1.26₹1.94
–₹0.08––
As declared that year–₹0.25––
Book value per share––₹11.96₹13.90
Dividend payout–7.8%––
Shareholder yield––1.4%0.0%
Market cap at the year end (₹ crore)36.343.319.228.2
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from.

Ratios

Standalone, years to March.Jfl Life Sciences PE ratio and valuation

RatioMar 2023Mar 2024Mar 2025Filed 28 JunMar 2026Filed 29 May
Revenue growth––76.2%60.1%
Operating profit growth––80.2%42.8%
Net profit growth–24.9%18.5%53.9%
Earnings per share growth–––54.0%
––10.5%15.0%
–––4.5 pts
From the net margin–––−0.4 pts
From asset turnover–––3.0 pts
From borrowing–––1.9 pts
Return on capital employed––14.4%15.7%
Cash conversion––−84.9%−67.9%
Interest cover2.55.06.75.1
Debt to equity––0.270.47
Receivable days––155148
Inventory days––128110
Payable days––9893
Cash conversion cycle, days––186165
Working capital days––169144
Asset turnover––1.141.47
Assets per rupee of net worth––1.822.09
Sales per rupee of plant––6.709.04
Capital spending to depreciation––0.403.14
Revenue growth and operating profit growth are left blank for the year to Mar 2024: between the two periods the company restated its earlier figures, so the two are on different bases and the change is not worked out. No balance sheet is on record for the years to Mar 2023 and Mar 2024, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
7.2%
Cash from operations against operating profit
−37.1%
Measure5 years3 years
Revenue growth, yearly rate–45.3%
Profit growth, yearly rate–31.6%
Return on equity, average–12.8%
Return on capital employed, average–15.1%
Operating margin, average9.5%9.6%
Net margin, average6.0%5.8%
Asset turnover, average–1.31
Cash conversion cycle, days, average–175
Interest cover, average4.85.6
Debt to equity, average–0.37

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations−4.3
Cash from investing−3.9
Cash from financing9.1
Capital spending3.4
Dividends paid0.0
Shares bought back0.0
Shares issued for cash0.0
Borrowings raised0.0
Borrowings repaid11.1

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2023Mar 2024Mar 2025Mar 2026
Altman Z-scorePublished threshold 1.81––3.132.45
Beneish M-scorePublished threshold −1.78–––−1.25
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–––16.49
Receivables growth less revenue growthOur threshold 0 percentage points–––−7.73
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––−25.27
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––0.74
Effective tax ratePublished threshold 17.16 per cent24.467.6332.2225.56
Tax charged less tax paid, % of profitOur threshold 10 percentage points––15.5325.56
A threshold marked as ours has no published figure; it is the line we read the check against.